|
|
||||||||
The Annals of Thoracic Surgery, Vol 57, 815-818, Copyright © 1994 by The Society of Thoracic Surgeons
DR Jones, RC Hill, A Vasilakis, MJ Hollingsed, GM Graeber, RA Gustafson, JL Cruzzavala and GF Murray
Durable, covalently bonded, heparin-coated cardiopulmonary bypass (CPB)
circuits with oxygenators have been developed. Proposed advantages of
heparin-coated CPB circuits include improved biocompatibility and
thromboresistance. The purpose of this study was to evaluate our experience
with heparin-coated CPB circuits in 20 patients. Heparin was given to
maintain an activated clotting time equal to or greater than 200 seconds,
while flow rates were kept equal to or greater than 2 L/min. Indications
for use of this circuit included recent stroke, posttraumatic injuries,
recent gastrointestinal bleeding, protamine allergies, combined cardiac and
noncardiac procedures, and ventricular assist. Mean heparin dosage was 0.50
+/- 0.18 mg/kg and protamine dosage was 57.14 +/- 39.36 mg. Postoperative
blood loss and transfusion requirements were minimal. Postoperative
complement levels of C3a and C5a were normal, suggesting excellent
biocompatibility. There were no deaths or perioperative complications.
Heparin-coated CPB circuits using a pump oxygenator can be used safely with
low-dose heparin administration in select patients requiring CPB.
ARTICLES
Safe use of heparin-coated bypass circuits incorporating a pump- oxygenator
Department of Surgery, West Virginia University, Morgantown.
This article has been cited by other articles:
![]() |
K. V. Arom and F. L. Grover Adult cardiac surgery during the first 50 years of the Southern Thoracic Surgical Association Ann. Thorac. Surg., November 1, 2003; 76(90050): S17 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Hill, S. Bannan, and P. G. Martin Low heparinization and heparin-bonded circuits. Ann. Thorac. Surg., October 1, 1997; 64(4): 1221 - 1222. [Full Text] |
||||
![]() |
C. Baufreton, P. G. M. Jansen, P. Le Besnerais, H. Velthuis, C. M. Thijs, C. R. H. Wildevuur, and D. Y. Loisance Heparin Coating With Aprotinin Reduces Blood Activation During Coronary Artery Operations Ann. Thorac. Surg., January 1, 1997; 63(1): 50 - 56. [Abstract] [Full Text] |
||||
![]() |
A. K. Ganjoo, M. G. Harloff, and W. D. Johnson CARDIOPULMONARY BYPASS FOR HEPARIN-INDUCED THROMBOCYTOPENIA: MANAGEMENT WITH A HEPARIN-BONDED CIRCUIT AND ENOXAPARIN J. Thorac. Cardiovasc. Surg., November 1, 1996; 112(5): 1390 - 1392. [Full Text] |
||||
![]() |
S. Daniel Review on the multifactorial aspects of bioincompatibility in CPB Perfusion, May 1, 1996; 11(3): 246 - 255. [Abstract] [PDF] |
||||
![]() |
R. L. Korn, C. A. Fisher, E. R. Livingston, N. Stenach, S. J. Fishman, V. Jeevanandam, and V. P. Addonizio THE EFFECTS OF CARMEDA BIOACTIVE SURFACE ON HUMAN BLOOD COMPONENTS DURING SIMULATED EXTRACORPOREAL CIRCULATION J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1073 - 1084. [Abstract] [Full Text] |
||||
![]() |
E. Ovrum, E. A. Holen, G. Tangen, F. Brosstad, M. Abdelnoor, M.-A. L. Ringdal, R. Oystese, and R. Istad Completely Heparinized Cardiopulmonary Bypass and Reduced Systemic Heparin: Clinical and Hemostatic Effects Ann. Thorac. Surg., August 1, 1995; 60(2): 365 - 371. [Abstract] [Full Text] |
||||
![]() |
F. L. Caes, Y. V. Van Belleghem, L. H. Missault, K. E. Coenye, and G. J. Van Nooten Surgical Treatment of Impending Paradoxical Embolism Through Patent Foramen Ovale Ann. Thorac. Surg., June 1, 1995; 59(6): 1559 - 1561. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |